

# Efficacy and Effectiveness of the PCV-10 and PCV-13 Vaccines in Preventing Pneumonia and Other Respiratory Disease

Pediatrics

145,

DOI: 10.1542/peds.2019-0377

Citation Report

#	ARTICLE	IF	CITATIONS
1	Response to “Letter to the Editor: Vaccine Failures in Pediatric Cases Caused by Streptococcus pneumoniae Serotype 19A” Human Vaccines and Immunotherapeutics, 2020, 16, 2511-2512.	3.3	0
2	CIRCULATING CLONAL COMPLEXES AND SEQUENCE TYPES OF STREPTOCOCCUS PNEUMONIAE SEROTYPE 19A WORLDWIDE: THE IMPORTANCE OF MULTIDRUG RESISTANCE: A SYSTEMATIC LITERATURE REVIEW. Expert Review of Vaccines, 2021, 20, 45-57.	4.4	10
3	Immune-Based Anti-Staphylococcal Therapeutic Approaches. Microorganisms, 2021, 9, 328.	3.6	3
4	Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease. Human Vaccines and Immunotherapeutics, 2022, 18, 1-8.	3.3	6
5	Streptococcus pneumoniae serotype 22F infection in respiratory syncytial virus infected neonatal lambs enhances morbidity. PLoS ONE, 2021, 16, e0235026.	2.5	0
6	Pneumonia and Invasive Pneumococcal Diseases: The Role of Pneumococcal Conjugate Vaccine in the Era of Multi-Drug Resistance. Vaccines, 2021, 9, 420.	4.4	21
7	Effect of prophylactic administration of antipyretics on the immune response to pneumococcal conjugate vaccines in children: a systematic review. Pneumonia (Nathan Qld ), 2021, 13, 7.	6.1	6
8	The incremental burden of invasive pneumococcal disease associated with a decline in childhood vaccination using a dynamic transmission model in Japan: A secondary impact of COVID-19. Computers in Biology and Medicine, 2021, 133, 104429.	7.0	9
9	Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance. Clinical Infectious Diseases, 2022, 74, 1639-1649.	5.8	14
10	Pneumococcal Conjugated Vaccines Decreased Acute Otitis Media Burden: A Population-Based Study in Israel. Journal of Pediatrics, 2021, 235, 233-238.e3.	1.8	12
11	Direct and indirect effects of 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in children hospitalised with pneumonia from formal and informal settlements in Mongolia: an observational study. The Lancet Regional Health - Western Pacific, 2021, 15, 100231.	2.9	4
12	Fouling Behavior during Sterile Filtration of Different Glycoconjugate Serotypes Used in Conjugate Vaccines. Pharmaceutical Research, 2021, 38, 155-163.	3.5	6
13	Invasive pneumococcal disease, pneumococcal pneumonia and all-cause pneumonia in Hong Kong during the COVID-19 pandemic compared with the preceding 5 years: a retrospective observational study. BMJ Open, 2021, 11, e055575.	1.9	15
14	Yields and Immunomodulatory Effects of Pneumococcal Membrane Vesicles Differ with the Bacterial Growth Phase. Advanced Healthcare Materials, 2022, 11, e2101151.	7.6	12
15	Pneumococcal Immunization Strategies for High-Risk Pediatric Populations Worldwide: One Size Does Not Fit All. Vaccines, 2021, 9, 1390.	4.4	4
16	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines, 2021, 9, 1338.	4.4	17
17	Systematic review of the efficacy, effectiveness and impact of high-valency pneumococcal conjugate vaccines on otitis media. Human Vaccines and Immunotherapeutics, 2022, 18, 1-18.	3.3	7
18	Effectiveness of Pneumococcal Vaccines on Otitis Media in Children: A Systematic Review. Value in Health, 2022, 25, 1042-1056.	0.3	5

#	ARTICLE	IF	CITATIONS
19	Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study. <i>Vaccine</i> , 2022, 40, 2733-2740.	3.8	10
20	Screening for Immunodeficiencies in Children With Invasive Pneumococcal Disease: Six-year Experience From a UK Children's Hospital. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, 575-578.	2.0	3
21	<i>Streptococcus pneumoniae</i> vaccination strategies and its expected impact on penicillin non-susceptibility in children under the age of five: Let's recap!. <i>Vaccine: X</i> , 2022, 11, 100170.	2.1	1
22	Distribution of Serotypes Causing Invasive Pneumococcal Disease in Children From High-Income Countries and the Impact of Pediatric Pneumococcal Vaccination. <i>Clinical Infectious Diseases</i> , 2023, 76, e1062-e1070.	5.8	16
23	Preclinical evaluation of an investigational 21-valent pneumococcal conjugate vaccine, V116, in adult-rhesus monkey, rabbit, and mouse models. <i>Vaccine</i> , 2022, , .	3.8	0
25	Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2+1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 609-620.	9.1	2
26	Economic evaluations of 13-valent pneumococcal conjugate vaccine: a systematic review. <i>Expert Review of Vaccines</i> , 2023, 22, 193-206.	4.4	6
27	Acute organ injury and long-term sequelae of severe pneumococcal infections. <i>Pneumonia (Nathan) Tj ETQq1 1 0.784314 rgBT /Overl</i>	0.1	5
28	CD4+ T-cell-mediated recognition of a conserved cholesterol-dependent cytolysin epitope generates broad antibacterial immunity. <i>Immunity</i> , 2023, 56, 1082-1097.e6.	14.3	0
29	Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive <i>Streptococcus pneumoniae</i> isolate serotypes in Canada: the SAVE study, 2011-20. <i>Journal of Antimicrobial Chemotherapy</i> , 2023, 78, i37-i47.	3.0	0
30	Dynamics of invasive pneumococcal disease in infants <2 years old following PCV7/13 implementation using two infant and a booster dose schedule: evidence for indirect protection of young infants, Israel, 2004 to 2019. <i>Eurosurveillance</i> , 2023, 28, .	7.0	1
32	Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data. <i>EClinicalMedicine</i> , 2023, 61, 102073.	7.1	0
34	Effectiveness of thirteen-valent pneumococcal conjugate vaccine to prevent serotype 3 invasive pneumococcal disease in Quebec in children, Canada. <i>Vaccine</i> , 2023, 41, 5486-5489.	3.8	1
35	A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	3.3	0
36	Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. <i>Vaccine</i> , 2023, 41, 5662-5669.	3.8	2
37	Federal Clinical Guidelines on Vaccination of pneumococcal infection in children and adults. <i>Profilakticheskaya Meditsina</i> , 2023, 26, 3.	0.6	1
38	PCV15, a pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease in infants and children. <i>Expert Review of Vaccines</i> , 2024, 23, 137-147.	4.4	0
39	Pneumococcal carriage, serotype distribution, and antimicrobial susceptibility in Papua New Guinean children vaccinated with PCV10 or PCV13 in a head-to-head trial. <i>Vaccine</i> , 2023, 41, 5392-5399.	3.8	1

#	ARTICLE	IF	CITATIONS
40	Multi-institutional Assessment of Otitis Media Epidemiology Using Real-world Data. International Journal of Pediatric Otorhinolaryngology, 2024, 179, 111921.	1.0	0